Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Zacks Investment Research
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?Cytokinetics is expected to beat Q3 2026 earnings estimates with a positive Earnings ESP of +0.44% and Zacks Rank #3 (Hold). The company is projected to report a quarterly loss of $1.50 per share with revenues of $42.01 million, up 2065.5% year-over-year. The stock has beaten consensus EPS estimates in 2 of the last 4 quarters.
GlobeNewswire Inc.
Cytokinetics to Announce Third Quarter Results on November 4, 2026Cytokinetics announced it will report third quarter 2026 results on November 4, 2026, followed by a conference call. The company highlighted positive progress with MYQORZO® (aficamten) approved across multiple regions for obstructive hypertrophic cardiomyopathy, and plans to submit a Supplemental New Drug Application in Q4 2026 following positive Phase 3 results for non-obstructive HCM treatment.
The Motley Fool
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?Amgen and Bristol Myers Squibb represent different investment approaches in pharmaceuticals. Amgen demonstrates stronger revenue growth (~10% YoY) with higher profitability margins (21%) but trades at a premium valuation (P/E 26.4x).
Bristol Myers Squibb offers significantly lower valuation (P/E 12.96x) and higher dividend yield (4.1%) with stronger free cash flow ($12.8B), though facing revenue headwinds and generic competition. For long-term dividend-focused investors, Bristol Myers Squibb is recommended despite near-term challenges.
Headlines open the publisher's site.
